Summit Announces PhaseOut DMD Did Not Meet Primary Endpoint
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
SunTrust Robinson Humphrey Downgrades Summit Therapeutics plc (SMMT) to Hold
June 27, 2018 1:51 PM EDTSunTrust Robinson Humphrey downgraded Summit Therapeutics plc (NASDAQ: SMMT) from Buy to Hold with a price target of $4.00 (from $22.00) after the company announced that the Phase II PhaseOut DMD study did not meet the pre-specified primary endpoint.
Ridinilazole, now the company's lead... More
Summit Therapeutics (SMMT) to Resumes Trading at 7:30 am ET
June 27, 2018 7:11 AM EDTSummit Therapeutics (NASDAQ: SMMT) to Resumes Trading at 7:30 am ET
... More